Transmucosal delivery of a dendritic cell-targeting intranasal nanovaccine boosts HIV-1 specific mucosal and systemic immune responses
Acta Biomaterialia · 2026-03 · 213 · 594-608
DOI: 10.1016/j.actbio.2026.02.021 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Biomaterialia, 2026-03. Verfasst von Yaotian Chang und 6 weiteren Autor:innen. Beteiligte Einrichtung: National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun, Jilin 130012, PR China. Hauptthemen laut MEDLINE: Dendritic Cells, Nanovaccines, Immunity, Mucosal, HIV-1. Die Arbeit nennt 60 Literaturangaben. Gefördert von: Jilin Scientific and Technological Development Program.
Abstract (Originalsprache)
The induction of secretory IgA (sIgA) on mucosal surfaces is crucial for developing vaccines that effectively prevent Human immunodeficiency virus type 1 (HIV-1) transmission. However, the mucosal barrier significantly limits antigen absorption, resulting in weak systemic and mucosal immune responses. In this study, a novel dual-function nanovaccine for intranasal administration of HIV-1 native-like envelope (Env) proteins was developed. Specifically, the amphiphilic polymer coating (DPPD2) was synthesized by conjugating P-D2, a peptide that targets the CD11c receptor on dendritic cells (DCs), to DSPE-PEG (DP). DPPD2 was then employed to surface-functionalize the amino-modified mesoporous silica nanoparticle (MSN) that was loaded with Env and Toll-like receptor 9 agonist CpG, resulting in a DC-targeting nanovaccine. DPPD2/Env/CpG@MSN could synergistically boost trans-mucosal penetration of Env proteins and the recruitment, antigen uptake and activation of submucosal DCs. More importantly, we found that DPPD2/Env/CpG@MSN promoted germinal center (GC) responses in the muco-associated lymphoid tissue and draining lymph nodes, further leading to significantly enhanced HIV-1-specific sIgA antibody levels in situ and distant mucosal sites. Furthermore, systemic immune responses such as serum neutralizing antibodies against heterologous HIV-1 pseudoviruses and systemic T cell immunity were improved. Our study introduces a unique functional intranasal nanovaccine, providing a basis for developing subunit vaccines against mucosal viral infections. STATEMENT OF SIGNIFICANCE: The development of effective strategies to prevent mucosal transmission of HIV-1 is crucial for combating AIDS. Current HIV-1 Env subunit vaccines have shown limited immunogenicity in mucosal immunity studies. This work developed an intranasal nanovaccine, DPPD2/Env/CpG@MSN, to synergistically enhance trans-mucosal penetration of the Env protein and its subsequent uptake by submucosal DCs. The results demonstrated that DPPD2/Env/CpG@MSN effectively boosted germinal center responses and antibody production. The levels of Env-specific sIgA antibodies were significantly elevated in both local and distant mucosal sites. Moreover, the nanovaccine also elicited robust Env-specific T cell immune responses in spleen. This design provides a promising strategy for enhancing the immunogenicity of HIV-1 subunit vaccines in mucosal vaccination.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun, Jilin 130012, PR China.
- Key Laboratory of Ministry of Education for Viral Pathogenesis & Infection Prevention and Control, School of Medicine, Jinan University, Guangzhou, Guangdong 510632, PR China.
- State Key Laboratory of Inorganic Synthesis & Preparative Chemistry, Jilin University, Changchun 130012, PR China.
- National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun, Jilin 130012, PR China; Key Laboratory for Molecular Enzymology and Engineering, the Ministry of Education, School…
Förderung
- Jilin Scientific and Technological Development Program
Zitieren
APA
Chang, Y., Xin, X., Wang, T., Liu, X., Wang, Q., Shi, Y., & Shan, Y. (2026). Transmucosal delivery of a dendritic cell-targeting intranasal nanovaccine boosts HIV-1 specific mucosal and systemic immune responses. Acta Biomaterialia, 213, 594-608. https://doi.org/10.1016/j.actbio.2026.02.021
Vancouver
Chang Y, Xin X, Wang T, Liu X, Wang Q, Shi Y, et al. Transmucosal delivery of a dendritic cell-targeting intranasal nanovaccine boosts HIV-1 specific mucosal and systemic immune responses. Acta Biomaterialia. 2026;213:594-608. doi:10.1016/j.actbio.2026.02.021
BibTeX
@article{Chang2026,
author = {Chang, Yaotian and Xin, Xiaoqian and Wang, Tongshuai and Liu, Xiaopan and Wang, Qingyu and Shi, Yuhua and Shan, Yaming},
title = {Transmucosal delivery of a dendritic cell-targeting intranasal nanovaccine boosts HIV-1 specific mucosal and systemic immune responses},
journal = {Acta Biomaterialia},
year = {2026},
volume = {213},
pages = {594--608},
doi = {10.1016/j.actbio.2026.02.021}
}
EUVIMED